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Single-Nucleotide-Specific siRNA Targeting in a
Dominant-Negative Skin Model
Robyn P. Hickerson1, Frances J.D. Smith2, Robert E. Reeves3, Christopher H. Contag3,4, Devin Leake5,
Sancy A. Leachman6, Leonard M. Milstone7, W.H. Irwin McLean2 and Roger L. Kaspar1
RNA interference offers a novel approach for developing therapeutics for dominant-negative genetic disorders.
The ability to inhibit expression of the mutant allele without affecting wild-type gene expression could be a
powerful new treatment option. Targeting the single-nucleotide keratin 6a (K6a) N171K mutation responsible for
the rare monogenic skin disorder pachyonychia congenita (PC), we demonstrate that small interfering RNAs
(siRNAs) can potently and selectively block expression of mutant K6a. To test whether lead siRNAs could
discriminate mutant mRNA in the presence of both wild-type and mutant forms, a dominant-negative PC cell
culture model was developed. As predicted for a dominant-negative disease, simultaneous expression of both
wild-type and mutant K6a resulted in defective keratin filament formation. Addition of mutant-specific siRNAs
allowed normal filament formation, suggesting selective inhibition of mutant K6a. The effectiveness of our
siRNA in skin was tested by co-delivering a firefly luciferase/mutant K6a bicistronic reporter construct and
mutant-specific siRNAs to mouse footpads. Potent inhibition of the fluorescent reporter was demonstrated
using the Xenogen IVIS200 in vivo imaging system. Additionally, wild type-specific siRNAs knocked down the
expression of pre-existing endogenous K6a in human keratinocytes. These results suggest that efficient delivery
of these ‘‘designer siRNAs’’ may allow effective treatment of numerous genetic disorders including PC.
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INTRODUCTION
In the decade and a half that has followed the initial
discovery of the underlying keratin 5 (K5) and K14 gene
mutations in epidermolysis bullosa simplex (EBS) (Bonifas
et al., 1991; Coulombe et al., 1991; Lane et al., 1992), there
has been a plethora of additional research identifying the
genetic basis of many epithelial fragility disorders with 20 of
the 54 human keratin genes now linked to genetic diseases,
including pachyonychia congenita (PC) (Irvine and McLean,
1999; McLean et al., 2005; Smith et al., 2005). Furthermore,
mutations have now been identified in genes encoding many
non-keratin intermediate filament proteins (Omary et al.,
2004). Collectively, these genetic disorders affect many non-
epithelial organ systems, and include muscular dystrophies,
neuropathies, inherited cataracts, progerias, and lipodystro-
phies; so keratinopathies are part of a large, clinically
heterogeneous group of disorders that share a common
dominant-negative pathomechanistic basis. Despite these
significant discoveries, little progress has been made in
developing therapeutics for these disorders or other domi-
nantly inherited genetic diseases. The discovery of RNA
interference (RNAi) and the demonstration that small inter-
fering RNAs (siRNAs) can potently and specifically inhibit
gene expression suggests that application of this technology
may result in novel therapeutics for skin disorders (Lewin
et al., 2005; Hengge, 2006; Prud’homme et al., 2006;
Dykxhoorn et al., 2006a). siRNA-based therapeutics are
currently in clinical trials for a number of non-skin diseases,
including age-related macular degeneration and respiratory
syncytial virus (Dykxhoorn and Lieberman, 2006).
PC is a dominant-negative skin disorder resulting
from mutations in any one of the inducible keratin genes
produced by keratinocytes: K6a, K6b, K16, and K17
(Smith et al., 2005; Leachman et al., 2005). Keratins are
type I and type II intermediate filament proteins that
form a cytoskeletal network within all epithelial cells.
Mutations in keratin genes result in aberrant cytoskeletal
networks, which present clinically as a variety of epithelial
fragility phenotypes such as PC (Smith, 2003). The majority of
keratin mutations are heterozygous missense mutations;
in some cases, small in-frame deletion/insertion mutations
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have been reported (see the Intermediate Filament Mutation
database; http://www.interfil.org). Most mutations occur in
the highly conserved helix boundary motif domains located
at either end of the a-helical keratin rod domain. There are
several recurrent mutations; the major one for K6a is at the
N171 site, at which the codon is either deleted or a single
base pair is mutated resulting in an amino-acid change (e.g.
N171K). These helix boundary mutations presumably prevent
normal intermediate filament formation (Steinert et al., 1993)
and compromise the structural integrity of the affected
keratinocytes, as seen ultrastructurally in the epidermis of
PC patients (McLean et al., 1995), resulting in the various PC
symptoms (Leachman et al., 2005).
PC was chosen as a prototype disorder for development of
siRNA-based therapeutics to treat genetic skin disorders as (1)
the molecular basis and cell type have been identified, (2) the
dominant-negative pattern potentially allows for downregulation
of the mutant keratin resulting in a therapeutic effect if wild-type
expression is unaffected, and (3) the major patient complaint is
localized pain, usually at small, defined pressure points on the
feet, suggesting that a small area can be locally treated
(Leachman et al., 2005; Smith et al., 2006). In this study, the
ability to design and identify potent siRNAs that can discriminate
a single-nucleotide change in K6a was investigated.
RESULTS
Differential inhibition of mutant K6a versus wild type by
specific siRNAs in tissue culture cells
A fluorescence-based tissue culture assay was developed to
screen for siRNAs that block mutant K6a expression with little
or no effect on wild-type expression. To readily monitor K6a
expression, both mutant and wild-type forms of K6a were
fused to the enhanced yellow fluorescent protein (EYFP)
reporter gene (Figure 1a). All possible siRNAs (19þ 2 format,
see Materials and Methods), designed to target the K6a
mRNA region containing a single-nucleotide change (C-A
at nucleotide position 513 resulting in the amino-acid
change, N171K), were tested (Figure 1b). Mutant-specific
siRNAs (K6a_513a.1–19) and wild-type-specific siRNAs
(K6a_513c.1–19) will be referred to as MUT.1–19 and
WT.1–19, respectively. siRNAs were co-transfected into
293FT cells with plasmids that express either K6a-WT/EYFP
or K6a-N171K/EYFP (Figure 1c). As a positive control,
enhanced green fluorescent protein (EGFP)-specific siRNAs
were co-transfected with the mutant and wild-type K6a/EYFP
constructs, resulting in 97 and 96% inhibition, respectively
(the 50% inhibitory concentration (IC50), values were 0.1 nM
against both constructs). It should be noted that EYFP and
EGFP are nearly identical in sequence, and there are no
nucleotide differences in the site targeted by the EGFP siRNA.
Several mutant-specific inhibitors showed activity against
mutant expression; however, each showed significant activity
against wild-type expression as well (i.e. MUT.2, 3, 5, 6, and
19). Other siRNAs were ineffective against either target (i.e.
MUT.8, 9, and 13–17). MUT.4, 10, and 12 showed
discrimination between mutant and wild-type K6a targets,
with MUT.4 and MUT.12 exhibiting the greatest potency.
MUT.4 reduced expression of mutant K6a by 88%, whereas
wild-type expression was reduced only by 23% (IC50 values
for MUT.4 against the mutant and wild-type constructs were
0.2 and 44 nM, respectively). MUT.12 reduced mutant K6a
expression by 82%, whereas the wild-type construct was
completely unaffected under the conditions tested (IC50 value
for MUT.12 against the mutant K6a target was 0.3 nM). The
data were corrected against cells transfected with the
irrelevant non-specific control (NSC4) siRNA, which did not
inhibit K6a/EYFP expression (o5% variation, data not
shown). It should be noted that no changes in cell
morphology or cell density were observed by bright-field
microscopy after siRNA treatment (data not shown).
The complete set of siRNAs that target the wild-type K6a
sequence (‘‘C’’ nucleotide at mRNA position 513) was also
tested. In general, the same inhibition pattern was observed
(see Figure S1). WT.4 siRNA had no effect on mutant K6a
expression, whereas wild-type expression was reduced by
65%. WT.12 inhibited wild-type expression by 80%, whereas
mutant expression was reduced by 18%. To test further the
requirement for an exact complementary match at position
513, additional siRNAs containing ‘‘U’’ or ‘‘G’’ residues at
this site were tested (Figure 2a). For each of the two sets of
siRNAs tested, only the exact match inhibited gene expres-
sion when co-transfected with the mutant or wild-type
K6a/EYFP expression plasmid (Figure 2b and see Figure S2
for quantitative data). These results indicate that mutant-
specific siRNAs can be designed that preferentially inhibit
mutant K6a gene expression over wild type and vice
versa (i.e. wild-type-specific siRNAs can selectively inhibit
wild-type expression).
Preferential inhibition of mutant K6a results in normal keratin
filament formation in a dominant-negative PC tissue culture
model
The siRNAs shown to selectively target mutant K6a/EYFP over
wild type were used to determine whether mutant-specific
siRNAs can preferentially inhibit mutant K6a protein synthe-
sis in PLC cells that have been transfected with a mixture of
both mutant and wild-type K6a expression constructs (tissue
culture model for the dominant-negative PC disorder).
Human PLC hepatocytes were used in these experiments,
as intermediate filaments are readily visualized in the cells
following transfection of exogenous keratins owing to their
flat morphology and simple keratin expression profile; PLC
cells express mainly K8 and K18 (Woll et al., 2005). The
ability of the identified inhibitors to selectively block mutant
K6a expression was assayed by analyzing the percentage of
cells in which keratin filaments were normal or disorganized
(aggregates). As seen in Figure 3, cells that were transfected
with the wild-type K6a/EYFP construct preferentially formed
keratin filaments, whereas cells transfected with the mutant
K6a/EYFP construct contained keratin aggregates with little, if
any, evidence of filament formation, as determined by
detection of the EYFP tag by fluorescence microscopy (76
vs 3% of the cells contained predominantly filaments when
transfected with the wild-type or mutant construct, respec-
tively). As expected for a dominant-negative mechanism,
cells transfected with a mixture of wild-type and mutant
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expression plasmids without siRNAs (data not shown) or with
irrelevant NSC4 siRNA were defective in keratin filament
formation (only 16% of the cells contained predominantly
keratin filaments). Co-transfection of cells with a mixture of
wild-type and mutant expression plasmids and siRNAs that
target mutant K6a (e.g. MUT.4 and MUT.12) rescued the
ability to form keratin filaments (85 and 79% of the cells
contained normal keratin filaments when co-transfected with
MUT.4 and MUT.12, respectively).
As a control, cells were co-transfected with the wild-type/
mutant expression plasmid mixture and the wild-type
versions of the lead siRNAs (WT.4 and WT.12). Virtually,
all of the cells contained keratin aggregates with few, if any,
filaments when co-transfected with the wild-type inhibitors
(92 and 97% of the cells contained predominantly aggregates
when co-transfected with the wild-type/mutant expression
plasmid mixture and WT.4 or WT.12 compared to 86% when
co-transfected with mutant expression plasmid alone and
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Figure 1. Complete siRNA sequence walk of the K6a-N171K single-nucleotide mutation site. (a) Schematic representation of the K6a/EYFP fusion
expression constructs showing the N171K mutation. (b) SiRNAs (19þ 2 format) were designed and synthesized to screen all possible target sequences
containing the single-nucleotide mutation (C513A) resulting in K6a-N171K. (c) Each K6a-N171K-specific siRNA was co-transfected in triplicate into
293FT tissue culture cells with 150 ng of either an expression vector containing K6a-N171K/EYFP fusion (dashed line) or a similar construct containing
K6a-WT/EYFP (solid line). K6a/EYFP levels were determined by FACS analysis 48 hours following transfection. The data were normalized against data from cells
transfected with NSC4 siRNA (nonspecific control).
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Figure 2. Exact sequence complementarity is necessary for inhibition of wild-type and mutant K6a expression by siRNAs at positions 4 and 12. (a) SiRNAs
corresponding to positions 4 and 12 were designed and synthesized to target all possible nucleotides at mRNA position 513 (site of single-nucleotide
mutation resulting in the N171K amino-acid change). Each siRNA (1 nM final concentration) was co-transfected in triplicate into 293FT tissue culture cells
with 150 ng of either (b) pK6a-WT/EYFP (c) or pK6a-N171K/EYFP plasmid, and expression was visualized by fluorescence microscopy using a green fluorescent
protein filter set. A representative image for each set of conditions is shown. Bar¼ 200 mm (bottom right panel).
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Figure 3. Treatment with K6a mutant-specific siRNA prevents keratin aggregates in a dominant-negative tissue culture model of PC. (a–g) PLC cells were
co-transfected with pK6a-WT/EYFP, pK6a-N171K/EYFP, or a mixture of pK6a-WT/EYFP and pK6a-N171K/EYFP expression plasmids (designed to mimic the
dominant-negative PC disease state) and 1nM siRNA. (a) pK6a-WT/EYFPþNSC4; (b) pK6a-N171K/EYFPþNSC4; (c) pK6a-WT/EYFPþ pK6a-N171K/
EYFPþNSC4; (d) pK6a-WT/EYFPþ pK6a-N171K/EYFPþMUT.4; (e) pK6a-WT/EYFPþ pK6a-N171K/EYFPþMUT.12; (f) pK6a-WT/EYFPþ pK6a-N171K/
EYFPþWT.4; (g) pK6a-WT/EYFPþ pK6a-N171K/EYFPþWT.12. Following a 48-hour incubation, the cells were fixed, stained with DAPI, and imaged by
fluorescence microscopy using DAPI and green fluorescent protein filter sets (a representative image is shown; bar¼10 mm). (h) The slides were analyzed and a
representative number of cells (see Materials and Methods) categorized as containing predominantly aggregates (red), predominantly filaments (green), or a
mixture of aggregates and filaments (yellow). This experiment was repeated three times with similar results.
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NSC4 siRNA). The increased keratin aggregation observed
after treatment with siRNAs targeting wild-type K6a may be
due to unintended silencing of endogenous K8 expressed in
the PLC cells (see Discussion).
Differential labeling of wild-type and mutant K6a
Co-transfection of PLC cells with both wild-type and mutant
K6a/EYFP expression constructs (both contain the same EYFP
tag) results in bright yellow/green aggregates when visualized
by fluorescence microscopy (Figure 3). To demonstrate
further the single-nucleotide specificity of the MUT.4 and
MUT.12 siRNAs, wild-type and mutant K6a were differen-
tially labeled with tomato fluorescent protein (tdTFP) (Shaner
et al., 2004) and EYFP, respectively. Wild-type K6a tagged
with tdTFP (pK6a-WT/tdTFP) was co-transfected with mutant
K6a tagged with EYFP (pK6a-N171K/EYFP) into PLC cells.
The ability to spectroscopically distinguish EYFP and tdTFP
allows the visualization of faint red keratin filaments even in
the presence of yellow/green keratin aggregates, which tend
to be very bright. No cells that expressed only EYFP or tdTFP
were found, suggesting that transient transfection of a given
cell results in quantitative uptake and expression of both
plasmids (data not shown). Similar results were observed with
constructs containing plum fluorescent protein (Shaner et al.,
2005) substituted for tdTFP; however, the tdTFP label was
brighter and therefore more easily visualized (data not
shown). As seen in Figure 4, cells co-transfected with pK6a-
WT/tdTFP and NSC4 siRNA were able to form keratin
filaments (Figure 4a), whereas cells transfected with pK6a-
N171K/EYFP resulted in aggregates (Figure 4b). In cells co-
transfected with a mixture of pK6a-WT/tdTFP and pK6a-
N171K/EYFP and NSC4 siRNA, red tdTFP-labeled filament
structures and yellow/green EYFP-labeled aggregates were
observed in some cells (Figure 4c), with the yellow/green
aggregates often colocalizing along the red filaments (data
not shown). Co-transfection of pK6a-WT/tdTFP and pK6a-
N171K/EYFP with mutant-specific inhibitors (MUT.4 and
MUT.12) resulted in robust knockdown of the K6a-N171K/
EYFP protein without affecting K6a-WT/tdTFP expression;
therefore, only red filaments were observed (Figure 4d and e).
Co-transfection of pK6a-WT/tdTFP and pK6a-N171K/EYFP
with wild-type-specific inhibitors (WT.4 and WT.12) resulted
in specific knockdown of K6a-WT/tdTFP protein expression
over K6a-N171K/EYFP, resulting in only yellow/green aggre-
gates (Figure 4f and g). Reversal of the tags on the wild-type
and mutant forms of K6a (i.e. pK6a-WT/EYFP and pK6a-
N171K/tdTFP) resulted in the expected yellow/green fila-
ments and red aggregates that were inhibited by their
respective siRNAs (data not shown).
SiRNA-mediated downregulation of pre-existing K6a expression
in human keratinocytes
Human HaCaT keratinocytes were transfected with K6a-
specific siRNAs (WT.4 and WT.12) to test their ability to
inhibit endogenous K6a (Figure 5). Ninety-six hours after
transfection, cells were lysed and the protein extract was
subjected to electrophoresis on a 4–12% bis-tris gel,
transferred to nitrocellulose, and incubated with a K6a-
specific antibody (Western blot analysis). It should be noted
that HaCaT cells express K6a but not K6b, as determined by
reverse transcriptase-PCR (F.J.D. Smith and W.H. Irwin
McLean, unpublished data). A strong K6a band was seen in
untreated HaCaT cells and those treated with the transfection
reagent RNAiMAX, while a dramatic reduction in the amount
of K6a protein was observed in cells treated with increasing
concentrations of the K6a-specific siRNAs, WT.4 or WT.12
WT+NSC4 MUT+NSC4 WT/MUT+NSC4
WT/MUT+MUT.4 WT/MUT+MUT.12 WT/MUT+WT.4 WT/MUT+WT.12
Figure 4. Differential labeling of wild-type and mutant K6a demonstrates single-nucleotide specificity in a PC disease model. PLC cells were co-transfected
with pK6a-WT/tdTFP (fusion with tdTFP), pK6a-N171K/EYFP, or a mixture of pK6a-WT/tdTFP and pK6a-N171K/EYFP expression plasmids and 1nM siRNA.
(a) pK6a-WT/tdTFPþNSC4; (b) pK6a-N171K/EYFPþNSC4; (c) pK6a-WT/tdTFPþ pK6a-N171K/EYFPþNSC4; (d) pK6a-WT/tdTFPþpK6a-N171K/
EYFPþMUT.4; (e) pK6a-WT/tdTFPþ pK6a-N171K/EYFPþMUT.12; (f) pK6a-WT/tdTFPþpK6a-N171K/EYFPþWT.4; (g) pK6a-WT/tdTFPþ pK6a-N171K/
EYFPþWT.12. After transfection (48 hours), the cells were fixed, stained with DAPI, and imaged by fluorescence microscopy using DAPI, green fluorescent
protein, and rhodamine filter sets (a representative image is shown; bar¼10 mm). This experiment was repeated three times with similar results.
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(76 and 85% reduction, respectively). It should be noted that
neither KA12 nor any other antibody currently available can
distinguish K6a from K6b; however, since HaCaT cells only
express K6a, the reduction in KA12 staining seen here is due
to siRNA targeting that mRNA. A 35 and 10% reduction in
K6a was observed upon treatment with mutant K6a-specific
inhibitors MUT.4 and MUT.12, respectively. Lamin A/C
expression is not inhibited by K6a-specific siRNA treatment
and was therefore used as a control to correct for differences
in sample loading. The wild-type K6a-specific knockdown
was confirmed at the mRNA level by Northern blot analysis
(data not shown). These results indicate that the wild-type
K6a siRNAs can inhibit endogenous K6a under conditions
where mutant K6a siRNAs have little effect, further demon-
strating single-nucleotide specificity.
Delivery and effectiveness of siRNAs in mouse footpad skin
To perform translational research with the K6a inhibitors in
an in vivo bioluminescence mouse model, a bicistronic
reporter gene/K6a (wild type or mutant) plasmid (Figure 6a)
was prepared that contains the firefly luciferase and K6a open
reading frames separated by the foot and mouth disease virus
2A element (Cao et al., 2005b; Wang et al., 2007). As
expected from the results using the EYFP reporter constructs
(Figures 1–4), both MUT.4 and MUT.12 siRNAs potently and
selectively inhibited mutant K6a expression as measured by
luciferase activity (Figure 6b). The IC50 values for MUT.4 and
MUT.12 against the fluc/K6a constructs were identical to
those against the K6a/EYFP constructs determined by FACS
(Figure 1). These siRNAs were next intradermally injected
into female FVB mouse footpads. Mouse footpad skin was
chosen over other mouse skin in part due to its greater
thickness, the absence of hair follicles, ease of access, and
relevance to PC (Wang et al., 2007). At the indicated time
points after gene transfer, luciferin was injected intraperito-
neally and the amount of light emitted as a result of fLuc
expression was determined using the IVIS in vivo imaging
system (Figure 6c shows the image at the 24-hour time point).
The non-invasive nature of this approach allows real-time
monitoring of reporter gene expression over multiple time
points in the same animals, thereby minimizing the number
of mice required and maximizing the amount and quality of
data obtained. Paws co-injected with the bicistronic target
containing mutant K6a along with mutant-specific siRNAs
(MUT.4 and MUT.12) show weak luciferase activity, com-
pared with control paws co-injected with pUC19 plasmid or
NSC4. Figure 6d shows the quantification over 3 days, the
bolded line representing the average of five mice per
treatment group. Although there is variability in the data,
there is a clear decrease in luciferase activity in the paws co-
injected with specific inhibitor compared with control paws,
indicating that these inhibitors are effective in intact skin.
DISCUSSION
Dominant-negative mutations result in a variety of diseases
because of gain of toxic function by the defective protein.
Many of these genes encode essential proteins; therefore,
treatment would necessitate selective inhibition of mutant
gene expression without affecting wild-type expression. The
ability of siRNAs to discriminate between highly homologous
sequences, even single-nucleotide changes, theoretically
allows for the treatment of any disease caused by a dominant
mutation, assuming delivery challenges can be overcome and
that sufficient wild-type protein is produced from the
unaffected gene.
Successful allele-specific silencing methods utilizing RNAi
technology to discriminate single-nucleotide mutations have
been reported recently, targeting either the mutation itself
(Brummelkamp et al., 2002; Ding et al., 2003; Schwarz et al.,
2006; Dykxhoorn et al., 2006b) or a single-nucleotide
polymorphism site associated with only the mutant mRNA
allele (Miller et al., 2003). In most of these studies, siRNAs
were designed such that the mutation was aligned with the
center (positions 9–11 from the 50 end) of the guide strand
based on the observation that this region directs mRNA
cleavage (Elbashir et al., 2001). As in the study reported by
Schwarz et al. (2006), we identified effective inhibitors by
testing all possible siRNAs (19þ2 format) against a specific
single-nucleotide mutation site. The selectivity conferred by
the mismatch between wild-type mRNA and MUT.10 siRNA
(located at position 10 from the 50 end of the guide strand;
Figure 1) is consistent with the position-dependent single-
nucleotide selectivity observed in previous studies (Brum-
melkamp et al., 2002; Ding et al., 2003; Miller et al., 2003;
Schwarz et al., 2006; Dykxhoorn et al., 2006b). However,
placement of the mismatch at positions 9 and 11 of the guide
strand showed moderate activity against the mutant mRNA
(21 and 37% reduction, respectively), with no effect on wild-
type expression.
In addition to MUT.10, our screen identified two other
highly selective and potent inhibitors, MUT.4 and MUT.12.
Each of these demonstrated higher potency than MUT.10,
while retaining selectivity, reducing mutant gene expression
by 88 and 82%, respectively. MUT.4 reduced wild-type
expression by 23%, whereas MUT.12 had no effect (Figure 1).
These inhibitors contain the single-nucleotide mutation
located at positions 4 and 12 from the 50 end of the guide
strand, respectively. Schwarz et al. (2006) reported that
siRNAs with the single-nucleotide mismatch at positions 9,
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Figure 5. Inhibition of endogenous K6a expression in human keratinocytes.
HaCaT cells were transfected with increasing concentrations of wild-type-
specific siRNAs (lanes 3–9 containing 0, 1, 2, 5, 10, 15, and 20 nM WT.4
or WT.12) and 20nM mutant-specific siRNAs (lane 10; MUT.4 or MUT.12).
Lane 1 is a ‘‘no treatment’’ control. After 96 hours, cells were harvested and
lysed in SDS-PAGE loading buffer, subjected to denaturing SDS-PAGE
analysis, and electroblotted to nitrocellulose. K6a expression was detected
by specific K6a antibody and visualized by the NBT/BCIP system. The blot
was subsequently reacted with an antibody specific to lamin A/C to show
equal lane loading and absence of generalized inhibition resulting from
siRNA treatment.
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10, 12, 13, 14, and 16 from the 50 end of the guide strand
were able to discriminate between the mutant and wild-type
SOD1 alleles. Although our results demonstrating that
mismatches at positions 10 and 12 also show allele-specific
discrimination, our data indicate that a mismatch at position
4 can discriminate as well. The siRNAs designed to target the
K6a gene with mismatches at positions 9, 13, 14, and 16
were inactive against both the mutant and wild-type alleles.
The reasons for these discrepancies are not known, and
further experiments are needed to elucidate the mechanisms
involved.
It has been suggested that to gain single-nucleotide
selectivity, a purine–purine mismatch is required between
the siRNA and the wild-type sequence (Dykxhoorn et al.,
2006b). A systematic study, in which all possible single-
nucleotide mismatches relative to a single potent siRNA were
monitored, demonstrated that any mismatch at position 10
(more so than at any other position) significantly reduced
silencing, regardless of the mismatch composition (Du et al.,
2005). In this study, all possible mismatches between siRNAs
(at positions 4 and 12) and K6a wild-type and mutant targets
were analyzed. Only siRNAs with exact complementarity
blocked gene expression, whereas all single-nucleotide
mismatches abrogated silencing, regardless of composition
(Figure 2b and see Figure S2 for quantitative data).
The levels of mutant keratin may not need to be
completely blocked and indeed may only need to be reduced
by 50% to show a phenotype reversal in PC (Cao et al., 2001;
Wong et al., 2005) or EBS, a skin disorder closely related to
PC (Cao et al., 2001). Like PC, EBS is a dominant-negative
keratin disorder, in which K5 (similar to K6) or K14 (similar to
K16 and K17) is mutated and is characterized by skin fragility
resulting in blisters caused by little or no trauma (Irvine and
McLean, 1999). In an attempt to generate an EBS mouse
model that mimics the dominant-negative disease at the
genetic level and also exhibits the EBS phenotype, Roop and
co-workers introduced a mutant K14 gene along with a neo
cassette in intron I (Cao et al., 2001). These heterozygous
mice appeared normal, showing no signs of blistering.
Semiquantitative reverse transcriptase-PCR analysis showed
mutant K14 levels at 50% of wild-type K14. Removal of the
neo cassette resulted in equivalent levels of mutant and wild-
type K14 expression as well as a disease phenotype,
suggesting that as little as 50% knockdown of the mutated
keratin may be sufficient to allow a normal phenotype.
Consistent with the EBS mouse model, in which complete
removal of mutant protein may not be necessary for a
therapeutic effect, our tissue culture model (developed to
mimic PC) demonstrated that treatment with K6a mutant-
selective siRNA results in a normal phenotype. Co-transfec-
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Figure 6. Inhibition of K6a (N171K)/fLuc reporter gene expression by specific siRNAs in a mouse footpad skin model. (a) Schematic representation of the
fLuc/K6a bicistronic expression constructs showing the N171K site and the foot and mouth disease virus 2A element (shaded). (b) 293FT cells were
co-transfected in triplicate with fLuc/K6a expression constructs in a 48-well plate format. After transfection (48 hours), luciferin was added and light emitted was
visualized using the Xenogen IVIS100 in vivo imaging system. Red color represents highest luciferase expression and purple lowest. (c) Mice (five per
group) were co-injected intradermally with 10 mg pK6a-N171K/fLuc expression plasmid and 10 mg of pUC19 plasmid (top panel, left paw), NSC4 siRNA (bottom
panel, left paw), MUT.4 siRNA (top panel, right paw), or MUT.12 siRNA (bottom panel, right paw). After 24 hours, luciferase expression in the footpads
was determined following intraperitoneal luciferin injection by whole-animal imaging using the Xenogen IVIS200 in vivo system. (d) Quantification of
luciferase activity in treated mice (24, 48, and 72 hours) was performed using LivingImage software and demonstrates reduction in fLuc signals in paws treated
with mutant-specific K6a siRNA compared with controls (pUC19 plasmid and NSC4 siRNA). Bolded line shows averaged results for each treatment.
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tion of MUT.10 (data not shown), which was less efficient
than MUT.4 and MUT.12, demonstrated similar results,
further suggesting that incomplete inhibition may be suffi-
cient to essentially ‘‘heal’’ the cell by allowing efficient
formation of filaments.
Skin represents an attractive target for nucleic acid-based
therapies owing to its ease of accessibility and the ability to
locally deliver therapeutic agents (Pines et al., 2001; Khavari
et al., 2002). Although the stratum corneum (the dead
cornified, outermost barrier layer of the epidermis) may be
difficult to penetrate, once nucleic acid is intradermally
delivered, keratinocytes are capable of taking up and
expressing naked DNA within hours as demonstrated in
mouse, pig, and human skin (Hengge et al., 1995; Hengge
et al., 1996; Sawamura et al., 2002). We have recently shown
that intradermal injection of a bicistronic luciferase-EGFP
expression plasmid into mouse footpads results in luciferase
expression, which is robustly silenced upon co-injection with
reporter-specific chemically stabilized or unmodified siRNA
(Wang et al., 2007). These data are consistent with previous
reports demonstrating expression of naked plasmid DNA in
vivo, and further suggest that naked, unmodified siRNAs can
be taken up by and function efficiently in skin.
Despite the rapid growth of RNAi technology, off-target
effects are not well understood and remain a concern
(Dykxhoorn and Lieberman, 2006). The K6a N171 region is
conserved among many type II keratins; however, the single-
nucleotide selectivity observed between wild-type and
mutant K6a suggests that our lead inhibitors will have little
or no effect on wild-type keratin expression. Owing to the
high-sequence conservation surrounding the K6a N171 site
with other keratins, if single nucleotide changes are tolerated
by the RISC complex, there may be downregulation of other
members of the keratin gene/protein family. Indeed, transfec-
tion of the wild-type versions of the lead inhibitors (WT.4 and
WT.12) into HaCaT and PLC cells showed inhibition of a
number of endogenous proteins in addition to K6a, including
K8. K5 was partially inhibited by MUT.4, but was not affected
by WT.12 (data not shown). As noted previously, K6b is not
expressed in HaCaT cells; however, owing to the exact
sequence identity with K6a at the target site, K6b is expected
to be inhibited upon treatment with wild-type K6a inhibitors.
Of particular importance to developing these inhibitors as
potential therapeutics, the lead mutant-specific K6a siRNAs
showed no off-target effects on wild-type keratin expression
nor on any other proteins on silver-stained two-dimensional
gels (data not shown), under conditions in which WT.4 and
WT.12 siRNAs potently downregulated endogenous K6a
expression. These data are consistent with the single-
nucleotide specificity observed in other experiments (Figures
1–5 and data not shown).
K8 and K18 are not expressed in HaCaT cells, but together
form the major intermediate filament network in simple
epithelial cells (Lane, 1993), including the PLC cells used in
this report (Woll et al., 2005). Sequence alignment (see Figure
S3) shows exact identity between K8 and K6a in the region
surrounding N171. Inhibition of K8 by WT.4 and WT.12
siRNAs may account for the decrease in the number of cells
with keratin filaments when PLC cells are treated with these
inhibitors (Figure 3b, bars vi and vii). One possible
explanation for the filaments observed in cells transfected
with the wild-type and mutant K6a expression plasmids is
that the K8/K18 network incorporates the wild-type K6a-EYFP
fusion protein. Therefore, the decrease observed in inter-
mediate filaments upon co-transfection with the wild-type
inhibitors may be due to knockdown of both wild-type K6a
and K8, thereby allowing mutant K6a to more efficiently pair
with K18 and disrupt filament formation. Although the wild-
type inhibitors decrease expression of multiple keratins, it is
important to note that the lead mutant-specific inhibitors only
target the N171K form of K6a and have little or no effect on
wild-type keratin expression.
The siRNAs reported in this study did not contain
modifications, which can increase stability (resistance to
nucleases) or enhance delivery. Unmodified siRNAs typically
have half-lives of less than 20minutes in serum, as analyzed
by PAGE (Chiu and Rana, 2003; Czauderna et al., 2003;
Layzer et al., 2004; Morrissey et al., 2005), although longer-
lived RNA duplexes have been reported (Braasch et al.,
2003). Although chemical modifications can greatly enhance
stability in serum, the increase in half-life does not always
result in a corresponding increase in functional activity
(Layzer et al., 2004). In addition, it should be noted that many
of the in vivo studies demonstrating disease protection were
performed using unmodified inhibitors (Giladi et al., 2003;
McCaffrey et al., 2003; Song et al., 2003; Wang et al., 2005;
Wesche-Soldato et al., 2005; Dykxhoorn et al., 2006a),
suggesting that serum stability is only one consideration in
developing an effective therapeutic. Indeed, owing to the
rapid clearance of siRNAs by the renal system (elimination
half-life of 6minutes; Soutschek et al., 2004), the identifica-
tion of modifications that allow directed delivery may be of
greater importance than enhanced stability for development
of siRNA-based therapeutics.
A number of chemically modified mutant and wild-type
K6a siRNAs were tested in tissue culture and mouse models
and were found to have potencies similar to those of
unmodified inhibitors (data not shown). Chemical modifica-
tions on the guide strand of the duplex that improve nuclease
resistance often enhance thermodynamic stability of target
hybridization, which in some instances resulted in loss of
single-nucleotide specificity. In this application, chemical
modifications for nuclease resistance are not expected to be
advantageous, as inhibitors are locally delivered via intra-
dermal injection to the affected skin, and unmodified siRNAs
may achieve better selectivity between wild-type and mutant
transcripts.
The potency and selectivity of the lead K6a siRNAs
developed against the N171K mutation site in K6a (MUT.4
and MUT.12) indicate that these may be ideal candidates for
clinical trials if efficient delivery can be achieved. We have
shown that the wild-type siRNA counterparts can efficiently
inhibit endogenous wild-type K6a expression in human
keratinocytes, whereas mutant-specific siRNAs show little
or no effect (Figure 5). We have also demonstrated the ability
to knock down EGFP expression in a transgenic EGFP mouse
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model by intradermal injection of unmodified EGFP-specific
siRNAs into mouse footpads (unpublished data). Taken
together, these data suggest that siRNA injection is a
potentially viable approach for patients suffering from
dominant-negative skin disorders, including PC. Further
investigation is needed to determine the extent of siRNA
distribution and the ability to inhibit endogenous gene
expression in intact skin.
MATERIALS AND METHODS
Design of siRNA
siRNAs (19þ 2 format; 19-nucleotide duplex with two 30 uracyl
nucleotide overhangs) were synthesized by Thermo Fisher Scientific,
Dharmacon Products (Lafayette, CO) to screen all possible target
sequences containing the N171K mutation previously described in
two multigeneration families and one sporadic case of PC (Lin et al.,
1999; Smith et al., 1999). This C4A point mutation occurs at
position 513 in the K6a coding sequence, numbering from the A in
the initiating ATG codon (gene name KRT6A, GenBank accession
no. NM 005554). The sense and antisense strands for K6a_513a.1
are 50-ACAGAUCAAGACCCUCAAAUU-30 and 50-P-UUUGAGG
GUCUUGAUCUGUUU-30, respectively. Sense and antisense
strands for siRNAs K6a_513a.2 through K6a_513a.19 were designed
similarly, and the sense strands are listed in Figure 1. The sense
strands for the wild-type counterparts are listed in Supplementary
material (see Figure S1). The SMARTselectedTM EGFP sequences for
the sense and antisense strands are 50-GCACCAUCUUCUUCAAG
GAUU and 50-P-UCCUUGAAGAAGAUGGUGCUU, respectively.
The NSC4 siRNA (inverted b-galactosidase sequence) sense and
antisense sequences are 50-UAGCGACUAAACACAUCAAUU and
50-P-UUGAUGUGUUUAGUCGCUAUU, respectively (Thermo
Fisher Scientific, Dharmacon Products, catalog no. D-001210).
Design of expression plasmids
K6a-EYFP fusion constructs. To generate expression constructs
for mutant (N171K) and wild-type K6a fusion proteins tagged with
EYFP, an EcoRI–XhoI fragment consisting of full-length human K6a
insert (contains 50 and 30 untranslated regions (UTR)) from IMAGE
clone 3639270 (MRC Geneservice, Cambridge, UK) was subcloned
into pcDNA3 (Invitrogen, Carlsbad, CA) generating clone 128. The
stop codon was replaced by a BamHI site (underlined) for in-frame
cloning into pEYFP-N1 (Clontech, Mountain View, CA) using the
QuickChange site-directed mutagenesis system (Stratagene, La Jolla,
CA) with the following primers: K6a.XBAM.F (50-AGCTATAAG
CACTCGGATCCGTCTGCTAGCTC-30) and K6a.XBAM.R (50-GAGC
TAGCAGACGGATCCGAGTGCTTATAGCT-30). Similarly, the N171K
mutation was introduced using the following primers: N171K.L (TC
AAGACCCTCAAAAACAAGTTTGC-30) and N171K.R (50GCAAACTT
GTTTTTGAGGGTCTTGA-30. DNA oligonucleotides were obtained
from Integrated DNA Technologies (Coralville, IA) and from MWG
Biotech (Ebersberg, Germany). The 2.5 kb HindIII/NotI-digested
PCR DNA fragments were further subcloned into pcDNA5/FRT
(Invitrogen) generating pTD100 and pTD101. The K6a 30UTR
was cloned downstream of EYFP into pTD100 and pTD101 by
PCR amplification using the following primers: K6a.30UTR.NOT.U
(50-AAGGAAAAAAGCGGCCGCAGGAAGAGCTATAAGCACT-30) and
K6a.30UTR.D (50-AAAGAAGGGCCCTCGAGGCAAAGAGCGAAGA
GCACAG-30), adding an upstream NotI site (underlined). The PCR
product was inserted into the pCRII-TOPO vector for amplification
using the TOPO TA cloning system (Invitrogen). The insert was
removed by NotI digestion (downstream Not1 site was located in
the pCRII-TOPO vector) and cloned into NotI-linearized pTD100
and pTD101, resulting in the expression plasmids pTD103 (K6a-WT/
EFYP) and pTD104 (K6a-N171K/EYFP), respectively. Clones were
verified by sequence analysis.
K6a-fLuc fusion constructs. To generate bicistronic constructs
expressing both firefly luciferase and mutant (or wild type) K6a, the
foot and mouth disease virus 2A element was used. The foot and
mouth disease virus 2A sequence results in pseudotermination of the
polypeptide encoded in the first open reading frame (fLuc in this
case), and then without disengaging from the mRNA, the second
open reading frame (K6a) is translated (Donnelly et al., 2001; de
Felipe et al., 2006). The K6a-EYFP-30UTRs of pTD103 and pTD104
(HindIII/PmeI digested followed by Klenow polymerase ‘‘fill-in’’ to
create ‘‘blunt ends’’) were cloned into the BamHI/HindIII sites of
pL2G (Cao et al., 2005a) (calf intestinal alkaline phosphatase-treated
and ‘‘blunt-ended’’ by Klenow polymerase), resulting in plasmids
pTD106 and pTD107. The 2A expression element, between the fLuc
and K6a coding regions in pTD106, was corrected by quick-change
mutagenesis using the following forward and reverse primers:
L2K.2a.F (50-CCAACCCTGGGCCCGGGATCCACCGGCCGGTCG
CCACCATGGCCAGCACATCCACCAC-30) and L2K.2a.R (50-GTGGT
GGATGTGCTGGCCATGGTGGCGACCGGCCGGTGGATCCCGG
GCCCAGGGTTGG-30), respectively. The resulting SgrAI/BstEII PCR
DNA fragment (700 bp) containing the corrected 2A region was
inserted into pTD106 and pTD107, resulting in pTD110 and
pTD111. The region coding for EYFP in pTD110 was deleted by
quick-change mutagenesis using the forward and reverse primers:
L2K.EYFP.F (50-CAGCAGGAAGAGCTATAAGCACTAAAGTGCGTC
TGCTAGCTCTCG-30) and L2K.EYFP.R (50CGAGAGCTAGCAGA
CGCACTTTAGTGCTTATAGCTCTTCCTGCTG-30), respectively. The
KpnI/EcoRI fragment (1,200bp) without EYFP was cloned into
pTD110 and pTD111, resulting in pTD114 and pTD115. Clones
were verified by sequence analysis.
K6a/tdTFP fluorescent protein constructs. The gene encoding
tdTFP was PCR-amplified from pRSET (td-tomato, generously
provided by Roger Tsien, UCSD) using the primers YFP.BAMHI.U
(50-TCGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGG-
30) and YFP.ECORV.D (50-TGGATATCGCTTTACTTGTACAGCTCGT
CCATGCC-30), adding an upstream BamHI site and a downstream
EcoRV site (sites underlined). The PCR product was inserted into the
pCRII-TOPO vector for amplification using the TOPO TA cloning
system (Invitrogen). The insert was removed and cloned into BamHI/
EcoRV-digested pK6a-WT/EYFP and pK6a-N171K/EYFP, resulting in
the expression plasmids pTD128 (K6a-WT/tdTFP) and pTD129 (K6a-
N171K/tdTFP), respectively. Clones were verified by sequence
analysis.
Cell culture
Human 293FT embryonic kidney cells (Invitrogen), human HaCaT
keratinocytes (Boukamp et al., 1988), and human PLC hepatoma
cells (ATCC CRL8024) were maintained in DMEM (CAMBREX/
BioWhittaker, Walkersville, MD) with 10% fetal bovine serum
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(HyClone, Logan, UT), supplemented with 2mM L-glutamine and
1mM sodium pyruvate (growth media).
Transient transfections of expression plasmids and siRNA
293FT transfections. The day before transfection, 293FT cells
were seeded at 8 104 cells/well in a 48-well plate resulting in 80%
cell confluency at the time of transfection. Cells were transfected
with Lipofectamine 2000 (Invitrogen) following the manufacturer’s
instructions. Cells were co-transfected (in triplicate) with a mixture of
150 ng expression plasmid, siRNA (final concentration 0.016–4 nM
per transfection), and pUC19 (to give a final nucleic acid
concentration of 400 ng per transfection), diluted to 25 ml in
optiMEM medium (Invitrogen). One microliter of Lipofectamine
2000 was diluted in 25ml of optiMEM medium and incubated at
room temperature for 5minutes. This mixture was added to the
nucleic acid and incubated for 20minutes at room temperature,
before addition to the plated cells.
Forty-eight hours following transfection, the cells were treated with
120ml trypsin (CAMBREX/BioWhittaker) for 15minutes at 371C.
Growth medium (120ml) was added and the sample was vigorously
mixed by pipetting. Each sample was diluted four-fold with PBS and
analyzed for EYFP expression by FACS (BD FACScan, BD Biosciences,
San Jose, CA) using the instrument’s channel FL1 (530nm emission
filter). A total of 5,000 cells per transfection were analyzed. The data
were generated by gating the cells and determining the percentage of
cells that dropped below the gate with and without siRNA treatment.
All data collected from cells treated with specific and nonspecific
siRNA were normalized to the value obtained from cells transfected
with expression plasmid, but no siRNA. Data obtained from cells
treated with the NSC4 siRNA were used to correct data obtained from
cells treated with specific siRNAs. Error bars reported for this and all
other experiments represent standard deviations.
Alternatively, to measure firefly luciferase expression, 48 hours
after transfection, 50 ml of 3mg/ml luciferin (in PBS) was added to
each well and incubated at room temperature for 3–5minutes. The
entire plate was imaged for 20 seconds using the IVIS in vivo imaging
system (Xenogen Corp., Alameda, CA).
PLC transfections. PLC hepatocytes were seeded at 4 104 cells/
well as described above for 293FT cells and co-transfected with wild
type, mutant, or a 3:7 mixture of wild-type and mutant K6a
expression plasmids tagged with either EYFP or tdTFP (200 ng total)
and 1 nM siRNA (final concentration), supplemented with pUC19 to
give a final nucleic acid concentration of 400 ng per transfection.
Twenty-four hours after transfection, the cells were treated with
120ml trypsin at 371C for 15minutes. Growth medium (880 ml) was
added and the cells were vigorously mixed by pipetting and 500ml
was transferred to four-well chamber slides (Labtek II, Nunc,
Rochester, NY). Forty-eight hours after transfection, the growth
medium was removed and the cells were washed twice with PBS
and fixed with 500ml ice-cold methanol/acetone (1:1) at room
temperature for 5minutes. The methanol/acetone was removed and
the slides were allowed to dry. The cells were stained with 500 ml of
0.4 mg/ml DAPI (Sigma, St Louis, MO) in PBS, mounted with
Histomount (National Diagnostics, Atlanta, GA), and imaged by
fluorescence microscopy (Zeiss Axioplan 2, ID 203090, with
FluoArc equipped with filter sets for DAPI, green fluorescent protein,
and rhodamine). The slides were analyzed and at least 20 cells per
transfection were categorized as containing predominantly aggre-
gates, predominantly filaments, or a mixture.
Human keratinocyte transfections. HaCaT keratinocytes were
transfected with RNAiMAX (Invitrogen) according to the manufac-
turer’s instructions for ‘‘reverse transfection.’’ Mutant- or wild-type-
specific siRNA (final concentration 0–20nM), supplemented with
EGFP siRNA to give a final total siRNA concentration of 20 nM, was
diluted in 50 ml optiMEM medium in a well of a 48-well plate. One
microliter of RNAiMAX lipofectamine (Invitrogen) was diluted in
50 ml of optiMEM medium and immediately added to the nucleic
acid solution and left for 20minutes at room temperature.
Trypsinized HaCaT cells (2 104 cells in 500ml) were then added
to the well and gently mixed before incubation.
Western blot analysis
HaCaT keratinocytes (96 hours post-transfection) were washed twice
with PBS, lysed with NuPAGE 1 loading dye/solubilization buffer
(lithium dodecyl sulfate buffer; Invitrogen), supplemented with
100mM dithiothreitol, subjected to electrophoresis in NuPAGE
Novex 4–12% bis-tris gels (Invitrogen), and electroblotted to
nitrocellulose (Invitrogen). K6a expression was detected by KA12
primary antibody (Progen Biotechnik GmbH, Heidelberg, Germany)
and goat anti-mouse IgG-alkaline phosphatase secondary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) and visualized by the
NBT/BCIP system (Promega, Madison, WI). The blot was subse-
quently reacted with a primary antibody specific to lamin A/C
(Upstate USA Inc., Charlottesville, VA) to show equal lane loading
and absence of generalized inhibition resulting from siRNA
treatment. Band intensities were quantified using ImageJ software
(http://www.rsb.info.nih.gov/ij/). The reported K6a values were
generated by dividing normalized K6a band intensites by the
average of the normalized lamin A and lamin C band intensities.
Mice
Six-week-old female FVB mice were obtained from the animal
facility of Stanford University. Animals were treated according to the
Guidelines for Animal Care of both NIH and Stanford University.
Mouse footpad injections and in vivo imaging
Mouse footpad injections were performed as described previously
(Wang et al., in press). In a typical experiment, a total volume of
50 ml PBS containing 10 mg siRNA and 10 mg of expression plasmid
was intradermally injected (28-gauge needle; Bectin Dickson and
Company, Franklin Lakes, NJ) into a mouse footpad. At the indicated
time points, the mice were imaged 10minutes after intraperitoneal
injection of luciferin (100 ml of 30mg/ml luciferin; 150mg/kg body
weight). Mice were sedated using isoflurane and live anesthetized
mice were imaged using the IVIS100 in vivo imaging system
(Xenogen Corp.). The resulting light emission was quantified using
LivingImage software (Xenogen Corp.), written as an overlay on Igor
image analysis software (WaveMetrics Inc., Lake Oswego, OR). Raw
values are reported as photons/second/cm2/sr.
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